TheraRadar
Clinical-Stage Companies / Trevi

Trevi

Pre-Approval PRO BETA
14
Total Trials
5
Phase 3
8
Phase 2
2
Recruiting
172
Score

Pipeline by Phase

Phase 3
5
Phase 2
8
Phase 1
6

Therapeutic Focus

Idiopathic Pulmonary Fibrosis Prurigo Nodularis Uremic Pruritus Pruritus Healthy Participants

Clinical Trials (14)

NCT05962151 Phase 2 COMPLETED

Refractory Chronic Cough Improvement Via NAL ER (RIVER)

Started: 11/30/2023

NCT05964335 Phase 2 COMPLETED

Cough Reduction in IPF With Nalbuphine ER

Started: 2/6/2024

NCT03497975 Phase 2 COMPLETED

PRISM Study-Pruritus Relief Through Itch Scratch Modulation

Started: 8/7/2018

NCT04030026 Phase 2 COMPLETED

A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough

Started: 10/29/2019

NCT02143973 Phase 2 COMPLETED

Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus

Started: 9/1/2014

NCT02174432 Phase 2 COMPLETED

Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis

Started: 8/15/2015

NCT02174419 Phase 2 COMPLETED

Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis

Started: 3/1/2015

NCT02143648 Phase 2 COMPLETED

Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus

Started: 6/1/2014

NCT07036029 Phase 1 RECRUITING

NAL ER IPF Respiratory Function and Safety Study

Started: 8/21/2025

NCT07487740 Phase 1 RECRUITING

A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants

Started: 2/27/2026

NCT04020016 Phase 1 COMPLETED

Study of Nalbuphine ER in Participants With Hepatic Impairment

Started: 6/12/2019

NCT07015398 Phase 1 COMPLETED

A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants

Started: 6/30/2025

NCT02373215 Phase 1 COMPLETED

Phase 1 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus

Started: 4/1/2013

NCT04018664 Phase 1 COMPLETED

Oral Abuse Potential Study of Nalbuphine

Started: 5/29/2018

Drug Candidates

NAL ER Placebo Nalbuphine ER Pirfenidone Nintedanib Nalbuphine ER Tablets Placebo Tablets Nalbuphine HCL ER nalbuphine HCl ER Nalbuphine HCl solution
Activity Status: Active
Last Trial Started: 2/27/2026
Last Trial Ended: 9/26/2025
Trials (12 months): 3
Completed Trials: 12
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.